Industry Newsprotein degradationclinical trialskymera therapeuticsfast track
Kymera Therapeutics Gains Analyst Attention Amid Volatility
6.1
Kymera Therapeutics shares have risen more than 28% over the past three months, with Wall Street projecting nearly 60% further upside as of January 12. Wolfe Research downgraded the stock to Peer Perform on January 6 and removed a $92 target, while BTIG and Citigroup maintained Buy ratings with $138 and $110 targets respectively. In December, the FDA granted Fast Track designation to KT-621 after positive BroADen Phase 1b results.
Key Points
- 1Stocks rose 28% in three months; Wall Street predicts ~60% upside by Jan 12.
- 2Analysts issue mixed ratings: Wolfe downgrades Jan 6, BTIG and Citi reaffirm Buy targets.
- 3FDA Fast Track for KT-621 after Phase 1b BroADen trial suggests clinical catalyst potential.
Scoring Rationale
Moderate investor-relevant update with official FDA action and analyst moves, limited by incremental novelty and promotional tone.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Search Campaigns by BudgetEasyHigh CPC Clicks & Poor Landing PagesMediumCampaign ROAS by Attribution ModelHard
250 free problems · No credit card
See all Ad Tech problems
